Aridis shares plunge ~25% as antibody drug fails Phase 3 trial in pneumonia by Technical Terrence Team 01/26/2023 0 gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...